Brought to you by 
Barr buys Duramed
Jul 2001
Executive Summary
Specialty generics and proprietary pharmaceuticals company Barr Laboratories has agreed to buy women's health care pharmaceutical specialist Duramed Pharmaceuticals in a stock swap. Barr says it will issue approximately 8.25mm of its common shares, worth $588.5mm (based on Barr's average trading price). Duramed stockowners get one Barr share for every 3.9 Duramed common held.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Payment Includes Stock
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Barr buys Duramed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice